About Us:

E-mail this page   Printable View

Our Mission and Vision

The Sabin Vision

The Sabin Vaccine Institute envisions a world without needless suffering from preventable infectious diseases.

The Sabin Mission

To actively reduce human suffering from infectious and neglected tropical diseases by providing greater access to vaccines and essential medicines and through a program of vaccine research, development and advocacy.


About Sabin

Our strength is in our ability to catalyze permanent change, implementing innovative solutions based upon hard, objective data. We know that harnessing the power of science will ensure real, lasting change.
  • We conduct biomedical research to develop vaccines and to prevent neglected diseases in developing countries.
  •  We campaign, advocating that all people in the US and abroad have access to available low-cost and safe vaccines and essential medicines for infectious and neglected tropical diseases.
  •  We provide essential medicines for neglected tropical diseases that afflict one billion of the world's poorest people--those who live on less than $2 per day.
  •  We convene thought leaders and policy makers and facilitate linkages between like-minded organizations.
  •  We partner throughout the world, working closely with governments, international organizations, the private sector, civil society and religious organizations.
  • We are independent and non-partisan.
  • We are a non-profit, non-governmental organization based in Washington, DC. Many of our activities are conducted in collaboration with our academic partner, The George Washington University. 

Since 2000, the Institute has increasingly focused on sponsoring and conducting research and development for vaccines to prevent neglected tropical diseases (NTDs), a group of disabling and poverty-promoting conditions in developing countries, such as human hookworm infection, schistosomiasis, and onchocerciasis. These represent the most common chronic infections of the world's poorest people. The Institute has gained international recognition for its commitment to combat these diseases of poverty through the use of vaccines as well as preventive drug therapy.

The Institute is developing and testing a new generation of antipoverty vaccines, i.e., recombinant protein vaccines for the major NTDs. These low-cost vaccines are specifically intended for the world's poorest people living on less than $2 per day. Sabin is the home of the Human Hookworm Vaccine Initiative (HHVI), an internationally-recognized product development partnership for the R&D, testing, and distribution of the world's first recombinant protein vaccine for human hookworm infection. HHVI is funded by the Bill and Melinda Gates Foundation.